Lexicon Enters a Global Licensing Agreement with Novo Nordisk for LX9851

Shots:Lexicon has granted Novo Nordisk exclusive global rights to develop, manufacture & commercialize LX9851 (oral ACSL5 inhibitor) in all indicationsAs per the deal, Lexicon will receive $45M upfront, ~$485M in regulatory & launch milestones, ~$475M in sales milestones, & tiered royalties from single to low-double-digit % of annual net sales. Lexicon will complete…

ByRidhi RastogiApril 2, 2025

INSIGHTS+

Insights+: The US FDA New Drug Approvals in May 2023

Shots:The US FDA approved 15 NDAs and 3 BLA in May 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 54 novel products in 2023In May 2023, the major highlights drugs were, Ayvakit approval for Indolent Systemic Mastocytosis, Rinvoq for Active Crohn's DiseasePharmaShots has…

BySenior EditorJune 21, 2023

VIEWPOINTS

Anand Patel, CMO, of Conquest Research and a Principal Investigator Shares Insights from the Significant Benefits of LX9211

Shots:Anand briefed PharmaShots about the study design and the results from the RELIEF-DPN-1 trial of its investigational drug LX9211 presented at the 16th Annual Pain Therapeutics SummitHe spoke about how LX9211 met its primary endpoints and how the drug shows considerable promise as a novel therapeutic medication for the treatment of painful diabetic…

BySenior EditorJune 19, 2023

Lexicon Enters a Global Licensing Agreement with Novo Nordisk for LX9851

Insights+: The US FDA New Drug Approvals in May 2023

Anand Patel, CMO, of Conquest Research and a Principal Investigator Shares Insights from the Significant Benefits of LX9211

Contact US

OUR INFORMATION

FOLLOW US